Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-10-24 4:30 pm Purchase | 2025-10-17 | 13G | C4 Therapeutics, Inc. CCCC | Bain Capital Life Sciences Fund II, L.P. | 6,060,000 6.250% | 6,060,000 (New Position) | Filing History |
| 2025-10-24 4:13 pm Purchase | 2025-10-17 | 13G | C4 Therapeutics, Inc. CCCC | RA Capital Management, L.P. | 9,441,256 9.900% | 9,441,256 (New Position) | Filing History |
| 2025-10-20 5:58 pm Purchase | 2025-10-17 | 13G | C4 Therapeutics, Inc. CCCC | Point72 Asset Management, L.P. | 22,647,647 9.900% | 21,333,900 (+1623.90%) | Filing History |
| 2025-08-07 12:50 pm Purchase | 2025-06-30 | 13G | C4 Therapeutics, Inc. CCCC | MORGAN STANLEY MS | 4,750,383 6.700% | 921,573 (+24.07%) | Filing History |
| 2025-07-16 7:02 pm Sale | 2025-06-30 | 13G | C4 Therapeutics, Inc. CCCC | BlackRock Inc. BLK | 1,756,613 2.500% | -3,134,766 (-64.09%) | Filing History |
| 2025-05-15 8:09 pm Purchase | 2025-03-31 | 13G | C4 Therapeutics, Inc. CCCC | ORBIMED ADVISORS LLC | 4,655,600 6.600% | 4,655,600 (New Position) | Filing History |
| 2025-05-15 4:52 pm Sale | 2025-03-31 | 13G | C4 Therapeutics, Inc. CCCC | RA Capital Management, L.P. | 0 0.000% | -4,878,000 (Position Closed) | Filing History |
| 2025-05-07 1:39 pm Purchase | 2025-04-30 | 13G | C4 Therapeutics, Inc. CCCC | Wasatch Advisors LP | 7,473,332 10.500% | 1,956,614 (+35.47%) | Filing History |
| 2025-02-03 1:59 pm Purchase | 2024-12-31 | 13G | C4 Therapeutics, Inc. CCCC | MORGAN STANLEY MS | 3,828,810 5.400% | 3,828,810 (New Position) | Filing History |
| 2024-11-14 7:53 pm Sale | 2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC | Point72 Asset Management, L.P. | 1,313,747 1.900% | -1,362,949 (-50.92%) | Filing History |
| 2024-11-14 6:43 pm Purchase | 2024-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | ORBIMED ADVISORS LLC | 2,925,900 4.200% | 2,925,900 (New Position) | Filing History |
| 2024-11-14 4:05 pm Sale | 2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC | Commodore Capital LP | 3,410,384 4.800% | -389,616 (-10.25%) | Filing History |
| 2024-11-14 3:30 pm Purchase | 2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC | Soleus Capital Master Fund, L.P. | 6,603,996 9.400% | 4,048,000 (+158.37%) | Filing History |
| 2024-11-14 1:22 pm Sale | 2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC | T. Rowe Price Associates, Inc. | 392,004 0.600% | -2,166,476 (-84.68%) | Filing History |
| 2024-11-14 09:01 am Purchase | 2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC | Lynx1 Capital Management LP | 6,880,527 9.900% | 3,746,131 (+119.52%) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC | BlackRock Inc. BLK | 4,891,379 7.100% | 0 (Unchanged) | Filing History |
| 2024-10-22 6:06 pm Purchase | 2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC | BlackRock Inc. BLK | 4,891,379 7.100% | 2,804,816 (+134.42%) | Filing History |
| 2024-07-10 06:47 am Sale | 2024-06-30 | 13G | C4 Therapeutics, Inc. CCCC | STATE STREET CORP STT | 2,994,948 4.350% | -4,158,332 (-58.13%) | Filing History |
| 2024-04-10 09:52 am Purchase | 2024-03-31 | 13G | C4 Therapeutics, Inc. CCCC | STATE STREET CORP STT | 7,153,280 10.430% | 7,153,280 (New Position) | Filing History |
| 2024-03-08 1:11 pm Sale | 2024-03-08 | 13G | C4 Therapeutics, Inc. CCCC | Wasatch Advisors LP | 5,516,718 8.000% | -1,622,231 (-22.72%) | Filing History |